Stay updated with breaking news from Interferon Beta. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
EQS-News: Atriva Therapeutics GmbH / Key word(s): Letter of Intent Atriva Therapeutics Announces Exclusive Letter Agreement for Reverse Takeover Transaction with Biocure Technology 18.09.2023 / 15:05 CET/CEST The issuer is solely responsible for the content of this announcement. Atriva Therapeut...
This report gives an insight into the global Interferon market and predicts the future growth prospects and the trends that may exhibit in the market...
Global Multiple Sclerosis Treatment Market Size, Study, By Product, Application, And Forecasts 2023-2031 Bharat Book Bureau Provides the Trending…
Response rates in a phase 2 trial of a novel therapy for skin-predominant dermatomyositis were favorable in patients failed by at least one prior standard therapy, prompting plans for a phase 3 trial.
Since the emergence of the first therapy, more than 20 agents with moderate to high efficacy have come to market for relapsing multiple sclerosis – but experts say that's both a blessing and problem.